Cara Therapeutics (CARA) Stock Forecast, Price & News

Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions

Is Cara Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cara Therapeutics stock.
View analyst ratings for Cara Therapeutics or view top-rated stocks.

Are investors shorting Cara Therapeutics?

Cara Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 5,350,000 shares, an increase of 30.2% from the April 30th total of 4,110,000 shares. Based on an average daily volume of 688,700 shares, the short-interest ratio is currently 7.8 days. Approximately 12.0% of the company's shares are sold short.
View Cara Therapeutics' Short Interest.

When is Cara Therapeutics' next earnings date?

Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Cara Therapeutics.

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) issued its quarterly earnings results on Monday, May, 9th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.04. During the same period in the prior year, the firm posted ($0.47) earnings per share.
View Cara Therapeutics' earnings history.

What price target have analysts set for CARA?

4 analysts have issued 1 year price objectives for Cara Therapeutics' shares. Their forecasts range from $20.00 to $30.00. On average, they expect Cara Therapeutics' stock price to reach $26.80 in the next twelve months. This suggests a possible upside of 225.2% from the stock's current price.
View analysts' price targets for Cara Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Cara Therapeutics' key executives?

Cara Therapeutics' management team includes the following people:

• Mr. Christopher A. Posner, Pres, CEO & Director (Age 52, Pay $431.9k)
• Dr. Derek T. Chalmers D.Sc., Ph.D., Co-Founder & Sr. Advisor (Age 58, Pay $580.93k)
• Mr. Thomas Charles Reilly, Chief Financial Officer (Age 49, Pay $670.94k) (LinkedIn Profile)
• Dr. Frédérique Menzaghi, Chief Scientific Officer and Sr. VP of R&D (Age 56, Pay $826.94k)
• Mr. Scott M. Terrillion, Chief Compliance Officer, Gen. Counsel & Corp. Sec. (Age 59, Pay $689.63k) (LinkedIn Profile)
• Dr. Joana Goncalves, Chief Medical Officer (Age 48, Pay $826.77k) (LinkedIn Profile)
• Mr. Richard Makara, VP, Head of Accounting, Controller & Principal Accounting Officer (Age 51)
• Mr. Eric Vandal, Sr. VP of Commercial
• Ms. Beth Weinberg, Sr. VP of Regulatory Affairs & QA

Who are some of Cara Therapeutics' key competitors?

Some companies that are related to Cara Therapeutics include Ironwood Pharmaceuticals (IRWD), Global Blood Therapeutics (GBT), Aurinia Pharmaceuticals (AUPH), ChemoCentryx (CCXI), HUTCHMED (HCM), Dynavax Technologies (DVAX), Ligand Pharmaceuticals (LGND), Travere Therapeutics (TVTX), Supernus Pharmaceuticals (SUPN), Xenon Pharmaceuticals (XENE), Arcus Biosciences (RCUS), Taro Pharmaceutical Industries (TARO), Xencor (XNCR), Sierra Oncology (SRRA) and Prothena (PRTA).
View all of CARA's competitors.

What other stocks do shareholders of Cara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), (CGC), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), (XXII), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.41%), Vanguard Group Inc. (6.05%), Farallon Capital Management LLC (4.67%), Disciplined Growth Investors Inc. MN (3.16%), State Street Corp (3.14%) and Chescapmanager LLC (2.19%). Company insiders that own Cara Therapeutics stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion and Thomas Charles Reilly.
View institutional ownership trends for Cara Therapeutics.

Which major investors are selling Cara Therapeutics stock?

CARA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Chescapmanager LLC, Charles Schwab Investment Management Inc., Davy Global Fund Management Ltd, Principal Financial Group Inc., JPMorgan Chase & Co., Jane Street Group LLC, and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Cara Therapeutics company stock in the last year include Christopher Posner, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion, and Thomas Charles Reilly.
View insider buying and selling activity for Cara Therapeutics or view top insider-selling stocks.

Which major investors are buying Cara Therapeutics stock?

CARA stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Pinnacle Associates Ltd., Dimensional Fund Advisors LP, Vanguard Group Inc., State Street Corp, Jupiter Asset Management Ltd., Royce & Associates LP, and Vident Investment Advisory LLC.
View insider buying and selling activity for Cara Therapeutics or or view top insider-buying stocks.

How do I buy shares of Cara Therapeutics?

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $8.24.

How much money does Cara Therapeutics make?

Cara Therapeutics has a market capitalization of $441.58 million and generates $23.03 million in revenue each year. The biopharmaceutical company earns $-88.44 million in net income (profit) each year or ($1.78) on an earnings per share basis.

How many employees does Cara Therapeutics have?

Cara Therapeutics employs 84 workers across the globe.

What is Cara Therapeutics' official website?

The official website for Cara Therapeutics is www.caratherapeutics.com.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at [email protected], or via fax at 203-567-1510.